Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.

ABSTRACT:

Background

Patients with metastatic urothelial carcinoma (mUC) have poor prognosis, so further development of novel combinations for these patients is needed.

Objective

To assess the safety and efficacy of eribulin mesylate (eribulin) with avelumab in mUC.

Design, setting, and participants

This was an open-label, phase 1b study in which patients with mUC who were cisplatin-ineligible and treatment-naïve or platinum-resistant were treated with eribulin and avelumab. A 3 + 3 design was used. The study was prematurely terminated because the free study drug became unavailable, but we performed extended follow-up for patients enrolled in the study.

Intervention

Patients received eribulin 1.1 mg/m² plus avelumab 10 mg/kg on days 1 and 15 in every 28-d cycl

SUBMITTER: Joshi M 

PROVIDER: S-EPMC8812202 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature